CRISPR Therapeutics announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact
- Crispr Therapeutics initiated with a Market Perform at Bernstein
- Crispr Therapeutics price target lowered to $55 from $63 at Citi
- Crispr Therapeutics initiated with a Buy at Bryan Garnier
- CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting